Gilead found a partner for test a long-term ART

According to press release of Lyndra Therapeutics, which specializes on development of long-term drugs, it managed to raise over $50 million as investments in its development. Gilead Sciences, a biotechnology company interested in a long-term ART market, was among the interested investors. The reason for this was the fact that the British ViiV is already conducting clinical trials of injectable forms of Cabotegravir and Rilpivirin, administered once every 8 and 4 weeks.

As follows from the Lyndra press release, all funds received as investments will be used to conduct Phase II clinical trials of a drug for the treatment of schizophrenia. The stated end date of trials - 2020 year.

However, in addition to the company's main goal in the coming months, it will also conduct tests of long-acting dosage forms for its partners, including Gilead, one of the world's largest manufacturers of medicines for treating HIV infection and hepatitis C.